New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
07:05 EDTTFXTeleflex signs new agreement with HealthTrust
Teleflex announced being awarded a new agreement for its line of ligation products with HealthTrust. The agreement was effective Dec. 1, 2012 and will provide HealthTrust's 1,400 hospital members access to Teleflex's comprehensive line of ligation products including reliable Weck branded Horizon, Auto Endo5 and Hem-o-lok products.
News For TFX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
07:20 EDTTFXTeleflex reports study results of Arrowg+ard technology effectiveness
Teleflex Incorporated announced that newly published research has further documented the ability of the company’s ARROW Central Venous Catheter with ARROWg+ard Blue Technology to reduce both catheter-related bloodstream infections and direct costs associated with treating those infections, even when the infection risk is already low. The peer‐reviewed retrospective study examined CVC usage in the subclavian insertion site. That location has been shown to be associated with lower overall infection risk, compared to the jugular and femoral infection sites.2 The study appears online in the respected American Journal of Infection Control, which is published by APIC, the Association for Professionals in Infection Control and Epidemiology. The antimicrobial catheter with ARROWg+ard Blue Technology outperformed an unprotected CVC in both infection reduction and total cost per patient. Within the study, the protected catheter achieved a zero infection rate of 0/1,000 catheter days. In contrast, the unprotected device was associated with a higher CRBSI rate of 2.12/1,000 catheter days. The results were statistically significant. The antimicrobial, protected catheter was also associated with prolonged CRBSI-free time compared to the unprotected catheter, including dwell times of up to 30 days without a bloodstream infection.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use